Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XBI-302 + Nivolumab in Anti-PD-1/L1 Resistant Gastric Cancer
NCT05001360Withdrawn
- Sponsor
- Fujian Medical University Cancer Hospital
- Start
- Oct 2021
- Primary completion
- Oct 2023
- Modality
- Live Biotherapeutic Products
- Countries
- 1
01
Overview
Open-label, single-arm trial of fecal microbiome transplant in gastric adenocarcinoma, esophagogastric junction adenocarcinoma (GEJA) and esophageal adenocarcinoma (EAC), sponsored by Fujian Medical University Cancer Hospital. Primary endpoint: Disease Control Rate at 24 weeks. Planned start Oct 2021; status: withdrawn.
02
Drugs
fecal microbiome transplant
03
Conditions
gastric adenocarcinomaesophagogastric junction adenocarcinoma (GEJA)esophageal adenocarcinoma (EAC)
Beyond the preview
Go deeper on NCT05001360.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05001360.